Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
Aileen Li, BSc Phm
Advertisement
Articles by Aileen Li, BSc Phm
Advertisement
Latest Updated Articles
- Private-payer Costs for Employees with Treatment-resistant Depression
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Breaking News: CVS Buys Rite Aid, Bartell Drugs
3
FDA Approves 1-Minute HIV Self-Test
4
Study: APOL1 Mutations in CKD Significantly Affect Cells Crucial to Kidney Function
5
